GlassScriptPhysician profile
Alberto Cabo Chan
NPI 1750314449
$456.63
in general payments reported to CMS, 2019-2025
10 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $82.74 · 2023: $182 · 2024: $91.21 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.62 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $110.21 | 2023-2025 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $68.70 | 2022 | |
| Novo Nordisk INC | $64.79 | 2022-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Tandem Diabetes Care, INC. | $47.87 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $38.07 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $32.25 | 2023-2024 | |
| Lilly USA, LLC | $22.12 | 2025 | Mounjaro, Zepbound |
| Insulet Corporation | $16.18 | 2024 | Omnipod |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Cabo Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.